Dokument-ID Dokumenttyp Verfasser/Autoren Herausgeber Haupttitel Abstract Auflage Verlagsort Verlag Erscheinungsjahr Seitenzahl Schriftenreihe Titel Schriftenreihe Bandzahl ISBN Quelle der Hochschulschrift Konferenzname Quelle:Titel Quelle:Jahrgang Quelle:Heftnummer Quelle:Erste Seite Quelle:Letzte Seite URN DOI Abteilungen OPUS4-11779 Wissenschaftlicher Artikel Verrua, Elisa; Ferrante, Emanuele; Filopanti, Marcello; Malchiodi, Elena; Sala, Elisa; Giavoli, Claudia; Arosio, Maura; Lania, Andrea Gerardo; Ronchi, Christina Lucia; Mantovani, Giovanna; Beck-Peccoz, Paolo; Spada, Anna Reevaluation of Acromegalic Patients in Long-Term Remission according to Newly Proposed Consensus Criteria for Control of Disease Acromegaly guidelines updated in 2010 revisited criteria of disease control: if applied, it is likely that a percentage of patients previously considered as cured might present postglucose GH nadir levels not adequately suppressed, with potential implications on management. This study explored GH secretion, as well as hormonal, clinical, neuroradiological, metabolic, and comorbid profile in a cohort of 40 acromegalic patients considered cured on the basis of the previous guidelines after a mean follow-up period of 17.2 years from remission, in order to assess the impact of the current criteria. At the last follow-up visit, in the presence of normal IGF-I concentrations, postglucose GH nadir was over 0.4 mu g/L in 11 patients (Group A) and below 0.4 mu g/L in 29 patients (Group B); moreover, Group A showed higher basal GH levels than Group B, whereas a significant decline of both GH and postglucose GH nadir levels during the follow-up was observed in Group B only. No differences in other evaluated parameters were found. These results seem to suggest that acromegalic patients considered cured on the basis of previous guidelines do not need a more intensive monitoring than patients who met the current criteria of disease control, supporting instead that the cut-off of 0.4 mcg/L might be too low for the currently used GH assay. 2014 581594 International Journal of Endocrinology urn:nbn:de:bvb:20-opus-117790 10.1155/2014/581594 Medizinische Klinik und Poliklinik I OPUS4-25014 Wissenschaftlicher Artikel Canu, Letizia; Puglisi, Soraya; Berchialla, Paola; De Filpo, Giuseppina; Brignardello, Francesca; Schiavi, Francesca; Ferrara, Alfonso Massimiliano; Zovato, Stefania; Luconi, Michaela; Pia, Anna; Appetecchia, Marialuisa; Arvat, Emanuela; Letizia, Claudio; Maccario, Mauro; Parasiliti-Caprino, Mirko; Altieri, Barbara; Faggiano, Antongiulio; Modica, Roberta; Morelli, Valentina; Arosio, Maura; Verga, Uberta; Pellegrino, Micaela; Petramala, Luigi; Concistrč, Antonio; Razzore, Paola; Ercolino, Tonino; Rapizzi, Elena; Maggi, Mario; Stigliano, Antonio; Burrello, Jacopo; Terzolo, Massimo; Opocher, Giuseppe; Mannelli, Massimo; Reimondo, Giuseppe A multicenter epidemiological study on second malignancy in non-syndromic pheochromocytoma/paraganglioma patients in Italy No studies have carried out an extensive analysis of the possible association between non-syndromic pheochromocytomas and paragangliomas (PPGLs) and other malignancies. To assess >the risk of additional malignancy in PPGL, we retrospectively evaluated 741 patients with PPGLs followed-up in twelve referral centers in Italy. Incidence of second malignant tumors was compared between this cohort and Italian patients with two subsequent malignancies. Among our patients, 95 (12.8%) developed a second malignant tumor, which were mainly prostate, colorectal and lung/bronchial cancers in males, breast cancer, differentiated thyroid cancer and melanoma in females. The standardized incidence ratio was 9.59 (95% CI 5.46-15.71) in males and 13.21 (95% CI 7.52-21.63) in females. At multivariable analysis, the risk of developing a second malignant tumor increased with age at diagnosis (HR 2.50, 95% CI 1.15-5.44, p = 0.021 for 50-59 vs. <50-year category; HR 3.46, 95% CI 1.67-7.15, p < 0.001 for >60- vs. <50-year). In patients with available genetic evaluation, a positive genetic test was inversely associated with the risk of developing a second tumor (HR 0.25, 95% CI 0.10-0.63, p = 0.003). In conclusion, PPGLs patients have higher incidence of additional malignant tumors compared to the general population who had a first malignancy, which could have an impact on the surveillance strategy. 2021 Cancers 13 22 urn:nbn:de:bvb:20-opus-250148 10.3390/cancers13225831 Medizinische Klinik und Poliklinik I